TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Brief Summary: The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.


Options:
A: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenograstim (GRANOCYTE)=GCSF, Drug: Sitagliptin (Januvia) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride (NaCl) 0.9 %, Drug: Gelatin | Intervention Type: DRUG; Name: Lenograstim (GRANOCYTE)=GCSF; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sitagliptin (Januvia); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride (NaCl) 0.9 %; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gelatin; Assigned to Arm(s): 2
C: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin
D: Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Dapagliflozin 10 mg; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Cohort Study With 52 Weeks Follow-up Investigating the Influence of Disease Perception on Functional Outcome Among Patients Referred From General Practice to Secondary Care for Treatment of Low Back Pain.
Brief Summary: The main purpose of the study is to investigate the importance of patients' beliefs regarding staying active despite low back pain, among patients referred from general practice to secondary care treatment in Denmark. It is hypothesised that patients believing that staying active will help them recover will have higher odds of a 30%-improvement in The Roland Morris Disability score after 52 weeks compared to patients disagreeing that staying active will lead to better recovery.


Options:
A: Arm Label: Standard mHealth Messaging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard mHealth Messaging Group | Arm Label: mHealth Messaging Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth Messaging Intervention Group | Intervention Type: BEHAVIORAL; Name: mHealth Messaging Intervention Group; Assigned to Arm(s): mHealth Messaging Intervention | Intervention Type: BEHAVIORAL; Name: Standard mHealth Messaging Group; Assigned to Arm(s): Standard mHealth Messaging
B: Arm Label: Chronic Disease Management; Type: N/A; Interventions: N/A
C: Arm Label: Low back pain patients; Type: N/A; Interventions: N/A
D: Arm Label: Paper PRO; Type: ACTIVE_COMPARATOR; Interventions: Other: Paper Survey | Arm Label: ePRO; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic Survey | Arm Label: Game-Motivated ePRO; Type: EXPERIMENTAL; Interventions: Other: The Guardians: A smartphone game | Intervention Type: OTHER; Name: The Guardians: A smartphone game; Assigned to Arm(s): Game-Motivated ePRO | Intervention Type: OTHER; Name: Paper Survey; Assigned to Arm(s): Paper PRO | Intervention Type: OTHER; Name: Electronic Survey; Assigned to Arm(s): ePRO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vagus Nerve Stimulation for Pediatric Intractable Epilepsy (VNS-PIE)
Brief Summary: Children with refractory epilepsy who are candidates for a treatment with vagus nerve stimulation will be prospectively randomized into 2 arms. Vagus nerve stimulation parameters are programmed and adjusted during outpatient clinic visits, within the normal clinical practice.


Options:
A: Arm Label: Lamotrigine Generic "A"/Generic "B"; Type: EXPERIMENTAL; Interventions: Drug: Lamotrigine Generic "A", Drug: Lamotrigine generic "B" | Arm Label: Lamotrigine Generic "B"/Generic "A"; Type: EXPERIMENTAL; Interventions: Drug: Lamotrigine Generic "A", Drug: Lamotrigine generic "B" | Intervention Type: DRUG; Name: Lamotrigine Generic "A"; Assigned to Arm(s): Lamotrigine Generic "A"/Generic "B", Lamotrigine Generic "B"/Generic "A" | Intervention Type: DRUG; Name: Lamotrigine generic "B"; Assigned to Arm(s): Lamotrigine Generic "A"/Generic "B", Lamotrigine Generic "B"/Generic "A"
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: lamotrigine (LAMICTAL) extended-relesase; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine (LAMICTAL) extended-release | Intervention Type: DRUG; Name: lamotrigine (LAMICTAL) extended-release; Assigned to Arm(s): lamotrigine (LAMICTAL) extended-relesase | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Vagus Nerve Stimualtor | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Vagus Nerve Stimualtor | Intervention Type: DEVICE; Name: PINS Vagus Nerve Stimualtor; Assigned to Arm(s): Control, Experimental
D: Arm Label: Generic A - Generic B - Brand - Generic A - Brand - Generic B; Type: EXPERIMENTAL; Interventions: Drug: Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", Drug: lamotrigine | Arm Label: Generic B - Brand - Generic A - Generic B - Generic A - Brand; Type: EXPERIMENTAL; Interventions: Drug: Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", Drug: lamotrigine | Arm Label: Brand - Generic A - Generic B - Brand - Generic B- Generic A; Type: EXPERIMENTAL; Interventions: Drug: Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", Drug: lamotrigine | Intervention Type: DRUG; Name: Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand"; Assigned to Arm(s): Brand - Generic A - Generic B - Brand - Generic B- Generic A, Generic A - Generic B - Brand - Generic A - Brand - Generic B, Generic B - Brand - Generic A - Generic B - Generic A - Brand | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Brand - Generic A - Generic B - Brand - Generic B- Generic A, Generic A - Generic B - Brand - Generic A - Brand - Generic B, Generic B - Brand - Generic A - Generic B - Generic A - Brand

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vagus Nerve Stimulation for Pediatric Intractable Epilepsy (VNS-PIE)
Brief Summary: Children with refractory epilepsy who are candidates for a treatment with vagus nerve stimulation will be prospectively randomized into 2 arms. Vagus nerve stimulation parameters are programmed and adjusted during outpatient clinic visits, within the normal clinical practice.


Options:
A: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: M106 VNS Therapy System | Intervention Type: DEVICE; Name: M106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
B: Arm Label: Transcutaneous auricular vagal stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: Transcutaneous auricular non-vagal stimulation; Type: SHAM_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ear vagus nerve stimulator; Assigned to Arm(s): Transcutaneous auricular non-vagal stimulation, Transcutaneous auricular vagal stimulation
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Vagus Nerve Stimualtor | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Vagus Nerve Stimualtor | Intervention Type: DEVICE; Name: PINS Vagus Nerve Stimualtor; Assigned to Arm(s): Control, Experimental
D: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: Model 106 VNS Therapy System | Intervention Type: DEVICE; Name: Model 106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Team-Based Delivery of Care in Outpatient Settings: An Experimental Investigation
Brief Summary: Through this research we intend to evaluate whether a team-based care delivery approach using daily huddles is effective in improving caregiver and patient outcomes in primary care setting. This approach is expected to not only lead to effective primary care delivery outcomes, but also result in greater team morale, reduced burnout, and a higher rate of innovation.


Options:
A: Arm Label: Retreat; Type: EXPERIMENTAL; Interventions: Other: Retreat | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Retreat; Assigned to Arm(s): Retreat
B: Arm Label: LOCI; Type: EXPERIMENTAL; Interventions: Behavioral: LOCI | Arm Label: Internet Based Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet Based Webinar Leadership Training | Intervention Type: BEHAVIORAL; Name: LOCI; Assigned to Arm(s): LOCI | Intervention Type: BEHAVIORAL; Name: Internet Based Webinar Leadership Training; Assigned to Arm(s): Internet Based Training
C: Arm Label: Staff of facilities for intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated leading, managing and governing for results model | Arm Label: Staff of facilities for control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional model | Intervention Type: BEHAVIORAL; Name: Integrated leading, managing and governing for results model; Assigned to Arm(s): Staff of facilities for intervention | Intervention Type: BEHAVIORAL; Name: Traditional model; Assigned to Arm(s): Staff of facilities for control
D: Intervention Type: BEHAVIORAL; Name: Leadership development program educational intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest (EROCA)
Brief Summary: In the U.S. alone, over 300,000 people per year have sudden out-of-hospital cardiac arrest (OHCA), and less than 1 out of 10 survive. The current standard practice for treating OHCA is to perform cardiopulmonary resuscitation (CPR) and Advanced Cardiovascular Life Support (ACLS) at the scene until either the heart is restarted or resuscitation efforts are considered hopeless and discontinued. An alternative strategy for those with refractory OHCA is expedited transport with ongoing mechanical CPR to an Emergency Department capable of performing extracorporeal cardiopulmonary resuscitation (ECPR). The purpose of study is to test if this strategy is feasible and beneficial.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Expedited Transport; Type: EXPERIMENTAL; Interventions: Device: Expedited Transport With Mechanical CPR | Intervention Type: DEVICE; Name: Expedited Transport With Mechanical CPR; Assigned to Arm(s): Expedited Transport
B: Arm Label: Intensive care survivors; Type: N/A; Interventions: N/A
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECCO2R to enable lower tidal volume mechanical ventilation; Type: EXPERIMENTAL; Interventions: Device: VV-ECCO2R to enable lower tidal volume mechanical ventilation | Intervention Type: DEVICE; Name: VV-ECCO2R to enable lower tidal volume mechanical ventilation; Assigned to Arm(s): ECCO2R to enable lower tidal volume mechanical ventilation
D: Arm Label: One Group; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amonocenter, Prospective, Randomized Clinical Trial to Investigate the Removal Time of Urinary Catheter After Laparoscopic Anterior Resection of the Rectum.
Brief Summary: Traditionally these catheters are retained for 7 days, because a higher incidence of urinary retention is related to early removal of the urinary catheter. However, recently Enhanced Recovery After Surgery presents that urinary catheters placed via the urethra can be withdrawn 48 hours after colon/rectal surgery in patients receiving epidural pain relief，but there is no clear data on the incidence of urine retention.Longer retaining time of urethral catheter would induce the urinary tract infection while early removal of urethral catheter is considered to develop acute retention of urine due to lack of sensation when the bladder is full. Taking the comfort and mobility for faster rehabilitation of patients into account, the investigators aim at obtain the optimal removal time of urinary catheter after after laparoscopic anterior resection of the rectum


Options:
A: Arm Label: clamping; Type: EXPERIMENTAL; Interventions: Procedure: to clamp or release the catheter for 2 days before removal | Arm Label: no clamping; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: to clamp or release the catheter for 2 days before removal; Assigned to Arm(s): clamping
B: Arm Label: Immediate catheter removal; Type: EXPERIMENTAL; Interventions: Procedure: Immediate catheter removal | Arm Label: Post op day 1 catheter removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Post op day 1 catheter removal | Intervention Type: PROCEDURE; Name: Immediate catheter removal; Assigned to Arm(s): Immediate catheter removal | Intervention Type: PROCEDURE; Name: Post op day 1 catheter removal; Assigned to Arm(s): Post op day 1 catheter removal
C: Arm Label: A B C; Type: EXPERIMENTAL; Interventions: Procedure: on Foley time | Intervention Type: PROCEDURE; Name: on Foley time; Assigned to Arm(s): A B C
D: Arm Label: Early removal group; Type: EXPERIMENTAL; Interventions: Procedure: Early removal group | Arm Label: Normal removal group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Normal removal group | Intervention Type: PROCEDURE; Name: Early removal group; Assigned to Arm(s): Early removal group | Intervention Type: PROCEDURE; Name: Normal removal group; Assigned to Arm(s): Normal removal group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia
Brief Summary: Introduction: Patients with dementia may suffer from poor sleep quality. Disturbance in the metabolism melatonin may have a role in the pathogenesis of sleep-wake cycle alterations in dementia.

Objective: To evaluate the efficacy of low dose exogenous melatonin in improving sleep quality.

Design: A single-center randomized, double-blinded, placebo-controlled study carried out on outpatients with dementia and sleep alterations.

Participants: The investigators calculated a 40 individuals aged 65 years or over with a diagnosis of mild-moderate dementia (Clinical Dementia Rating 1-2).

Intervention: Patients were randomized to receive either 5 mg of melatonin or placebo every night for 8 weeks.

Measurements: The primary outcome was sleep quality according to the Pittsburgh Sleep Quality Index (PSQI).


Options:
A: Arm Label: Melatonin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Melatonin 5 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Melatonin 5 mg; Assigned to Arm(s): Melatonin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: SAR110894 - 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 2 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (for SAR110894), Drug: Donepezil | Intervention Type: DRUG; Name: SAR110894; Assigned to Arm(s): SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg | Intervention Type: DRUG; Name: placebo (for SAR110894); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): Placebo, SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg
C: Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Mirtazapine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia
Brief Summary: Introduction: Patients with dementia may suffer from poor sleep quality. Disturbance in the metabolism melatonin may have a role in the pathogenesis of sleep-wake cycle alterations in dementia.

Objective: To evaluate the efficacy of low dose exogenous melatonin in improving sleep quality.

Design: A single-center randomized, double-blinded, placebo-controlled study carried out on outpatients with dementia and sleep alterations.

Participants: The investigators calculated a 40 individuals aged 65 years or over with a diagnosis of mild-moderate dementia (Clinical Dementia Rating 1-2).

Intervention: Patients were randomized to receive either 5 mg of melatonin or placebo every night for 8 weeks.

Measurements: The primary outcome was sleep quality according to the Pittsburgh Sleep Quality Index (PSQI).


Options:
A: Arm Label: Suvorexant HD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant High Dose (HD) | Arm Label: Suvorexant LD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant Low Dose (LD) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Suvorexant High Dose (HD); Assigned to Arm(s): Suvorexant HD | Intervention Type: DRUG; Name: Suvorexant Low Dose (LD); Assigned to Arm(s): Suvorexant LD | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo
C: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Melatonin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Melatonin 5 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Melatonin 5 mg; Assigned to Arm(s): Melatonin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Fructose Restriction on Liver Steatosis
Brief Summary: Nonalcoholic fatty liver disease (NAFLD) is an emerging health problem as it can lead to end stage liver failure and cardiovascular complications. Diet play an important role in the development of NAFLD. Many studies have addressed the effects of added fructose on NAFLD. To date, little attention has been paid to the effects of a diet devoid of fructose. Therefore, the investigators aim to study the effects of fructose restriction on hepatic fat accumulation and vascular function using a double-blind randomized placebo-controlled design.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load diet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
B: Arm Label: Carbohydrate-restricted diet; Type: EXPERIMENTAL; Interventions: Other: Carbohydrate-restricted diet | Arm Label: Control, low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Control, low-fat diet | Intervention Type: OTHER; Name: Carbohydrate-restricted diet; Assigned to Arm(s): Carbohydrate-restricted diet | Intervention Type: OTHER; Name: Control, low-fat diet; Assigned to Arm(s): Control, low-fat diet
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): Exercise
D: Arm Label: Glucose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucose | Arm Label: Fructose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fructose | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucose; Assigned to Arm(s): Glucose | Intervention Type: DIETARY_SUPPLEMENT; Name: Fructose; Assigned to Arm(s): Fructose

Answer: D